Omnicell Appoints Perry A. Genova as Chief Technology Officer

Perry A. Genova, Chief Technology Officer, Omnicell | Effective March 31, 2025・ Photo Credit: Omnicell

Corporate Business News Sponsored by Business Watch Global

FORT WORTH, Texas, March 22, 2025 (VSNewsNetwork.com) — Medical technology company Omnicell, Inc. has appointed Perry A. Genova, PhD, as Senior Vice President and Chief Technology Officer, effective March 31, 2025.

According to the company, Genova will lead Omnicell’s global technology strategy and engineering organization, with a focus on addressing challenges in medication and supply management across healthcare settings.

@VSNewsNetwork

•

@VSNewsNetwork •

Genova brings more than 25 years of experience in product development, strategic planning, and regulatory compliance. He has held senior leadership positions at EndoQuest Robotics, Titan Medical USA, Centauri Robotic Surgical Systems, Oncoscope, GSK plc, and Kos Pharmaceuticals. His achievements include developing a reservoir insulin device, building an $800 million division at Kos Pharmaceuticals, and holding 58 U.S. patents.

"We believe Perry’s entrepreneurial mindset will be pivotal to advancing our multi-year, outcome-centric growth strategy as we strive to deliver clinical and operational outcomes for our customers. His focus on building trust and collaboration among strategic partners and internal and external stakeholders will help to drive forward our purpose to transform medication management across all care settings," said Nnamdi Njoku, Executive Vice President and Chief Operating Officer at Omnicell.

Omnicell, founded in 1992, offers robotics, software, and data-driven services designed to improve outcomes in pharmacy and nursing care delivery.

For more information, visit www.omnicell.com.

Source: Omnicell, Inc.